Source disclosure: February 17, 2026
TAIKO PHARMACEUTICAL CO.,LTD. [4574.T]
TOKYO, Feb 17 (Pulse News Wire) – Taiko Pharmaceutical CO.,LTD. (4574.T) reported its fiscal year 2025 earnings, showing a net profit of ¥923 million compared to ¥898 million in the previous year.
Despite a slight decline in overall sales due to reduced production of key products like Zhenglu Wan, the company's operating and ordinary profits exceeded expectations. Infection management revenues increased significantly, contributing positively to the bottom line. However, the medical product division saw a reduction in sales and profitability.
Notably, the company’s cash flow remained robust, driven by strong operational performance and investment activities. Looking ahead, Taiko forecasts continued growth in overseas markets and plans strategic investments in new products and marketing efforts to bolster future earnings. The company also announced a resumption of dividend payments after a five-year hiatus, planning to distribute ¥3.3 per share in the upcoming fiscal year.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing